Ativação elétrica ventricular na ressincronização cardíaca caracterizada pelo mapeamento eletrocardiográfico de superfície / Ventricular electrical activation in cardiac resynchronization as characterized by body surface potential mapping

OBJETIVOS: Avaliar a ativação elétrica cardíaca usando Mapeamento Eletrocardiográfico de Superfície (MES), em pacientes com ICC e bloqueio de ramo esquerdo [BRE] submetidos a terapia de ressincronização cardíaca (CRT) com implante de marca-passo átrio-biventricular (MP-BIV). MÉTODOS: Foram analisados os tempos médios de ativação elétrica cardíaca no ventrículo direito (tempo médio de ativação do VD [mVD]), área ântero-septal (mAS), e ventrículo esquerdo (mVE), de 28 pacientes (idade média 61,2±9,5 anos, ICC classe III-IV NYHA, fração de ejeção <40 por cento, BRE com QRS médio 181,2±19,4ms, SAQRS= -8,5°±68,6°), mostrados nos mapas de linhas isócronas do MES, antes e após implante de marca-passo átrio-biventricular, e comparados a valores obtidos em um grupo controle composto de indivíduos normais [GNL], em três situações: (1) BRE nativo, (2) estimulação do VD; e (3) estimulação átrio-biventricular. RESULTADOS: situação (1): mVD e mAS foram semelhantes (41,0±11,8ms x 43,6±13,4ms), com mVE tardio (81,0±12,5ms, p<0,01) perdendo o sincronismo com o VD e a área ântero-septal; situação (2): mVD foi maior que no GNL (86,8±22,9ms, p<0,001), com maior diferença entre mAS e mVE (63,4±20,7ms x 102,7±20,3ms; p<0,001); situação (3): mVE e mVD foram semelhantes (72,0±32,0ms x 71,6±32,3ms), mVD foi maior que no GNL e BRE nativo (71,6±32,3ms x 35,1±10,9ms e 41,0±11,8ms; p<0,001), mAS se aproximou do GNL e BRE nativo (51,3±32,8ms x 50,1±11,4ms e 43,6±13,4ms). CONCLUSÃO: Pelo mapeamento eletrocardiográfico de superfície, tempos de ativação semelhantes no VD e VE e próximos daqueles da região ântero-septal indicam padrões de ativação ventricular sincronizada em portadores de ICC e BRE durante estimulação átrio-biventricular.

OBJECTIVES: To assess cardiac electrical activation by using body surface potential mapping (BSPM), in patients with congestive heart failure (CHF) and left bundle branch block (LBBB) undergoing cardiac resynchronization therapy (CRT) with biventricular pacemaker (BIV-PM) implantation. METHODS: Mean cardiac electrical activation times were analyzed in the right ventricle (RV) (mean RV activation time = mRV), anteroseptal area (mAS), and left ventricle (mLV) of 28 patients (mean age 61.2 ± 9.5 years; NYHA class III-IV CHF; ejection fraction <40 percent; LBBB of mean QRS 181.2±19.4ms, SAQRS -8.5°±68.6°), as shown in their BSPM isochronous maps, before and after implantation of atriobiventricular pacemaker, comparing those with values obtained from a control group of normal individuals [CG], in three situations: (1) native LBBB; (2) RV pacing; and (3) atriobiventricular pacing. RESULTS: Situation (1): mRV and mAS values were similar (41.0±11.8ms x 43.6±13.4ms), with delayed mLV (81.0±12.5ms, p<0.01) and asynchronous with RV and AS areas; situation (2): mRV was greater than in CG (86.8±22.9ms, p<0.001), with greater difference between mAS and mLV (63.4±20.7ms vs. 102.7±20.3ms; p<0,001); situation (3): mLV and mRV were similar (72.0±32.0ms vs. 71.6±32.3ms), mRV was greater than in CG and native LBBB (71.6±32.3ms vs. 35.1±10.9ms and 41.0±11.8ms; p<0.001), and mAS was close to CG and native LBBB values (51.3±32.8ms vs. 50.1±11.4ms and 43.6±13.4ms). CONCLUSION: The body surface potential mapping showed that RV and LV activation times which are similar, and are close to those of the AS area, suggest patterns of synchronized ventricular activation in patients with CHF and LBBB during atriobiventricular pacing.

Exercício e insuficiência cardíaca. Estudo da relaçäo da gravidade da doença com o limiar anaeróbico e o ponto de compensaçäo respiratório / Exercise and heart failure. Relation of the severity of the disease to the anaerobic threshould and the respiratory compensation point

OBJECTIVE - To identify, the anaerobic threshold and respiratory compensation point in patients with heart failure. METHODS - The study comprised 42 Men,divided according to the functional class (FC) as follows: group I (GI) - 15 patients in FC I; group II (GII) - 15 patients in FC II; and group III (GIII) - 12 patients in FC III. Patients underwent a treadmill cardiopulmonary exercise test, where the expired gases were analyzed. RESULTS - The values for the heart rate (in bpm) at the anaerobic threshold were the following: GI, 122_27; GII, 117_17; GIII, 114_22. At the respiratory compensation point, the heart rates (in bpm) were as follows: GI, 145_33; GII, 133_14; GIII 123_22. The values for the heart rates at the respiratory compensation point in GI and GIII showed statistical difference. The values of oxygen consumption (VO2) at the anaerobic threshold were the following (in ml/kg/min): GI, 13.6_3.25; GII, 10.77_1.89; GIII, 8.7_1.44 and, at the respiratory compensation point, they were as follows: GI, 19.1_2.2; GII, 14.22_2.63; GIII, 10.27_1.85. CONCLUSION - Patients with stable functional class I, II, and III heart failure reached the anaerobic threshold and the respiratory compensation point at different levels of oxygen consumption and heart rate. The role played by these thresholds in physical activity for this group of patients needs to be better clarified

Hormônio do crescimento na otimizaçäo do tratamento da insuficiência cardíaca refratária / Growth hormone for optimization of refractory heart failure treatment

It has been reported that growth hormone may benefit selected patients with congestive heart failure. A 63-year-old man with refractory congestive heart failure waiting for heart transplantation, depending on intravenous drugs (dobutamine) and presenting with progressive worsening of the clinical status and cachexia, despite standard treatment, received growth hormone replacement (8 units per day) for optimization of congestive heart failure management. Increase in both serum growth hormone levels (from 0.3 to 0.8 mg/l) and serum IGF-1 levels (from 130 to 300ng/ml) was noted, in association with clinical status improvement, better optimization of heart failure treatment and discontinuation of dobutamine infusion. Left ventricular ejection fraction (by MUGA) increased from 13 percent to 18 percent and to 28 percent later, in association with reduction of pulmonary pressures and increase in exercise capacity (rise in peak VO2to 13.4 and to 16.2ml/kg/min later). The patient was"de-listed" for heart transplantation. Growth hormone may benefit selected patients with refractory heart failure